Belén Fernández Requena

Dr. Belén Fernández Requena

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
BRBelén Fernández Requena
Belén Fernández Requena
SNSajid Nadeem
Sajid Nadeem
VRVineel P. Reddy
Vineel P. Reddy
VNVanessa Naidoo
Vanessa Naidoo
JGJoel N Glasgow
Joel N Glasgow
CRCarolina González Riaño
Carolina González Riaño
Accurate lipid annotation is crucial for understanding the role of lipids in health and disease and identifying therapeutic targets. However, annotating the wide variety of lipid species in biological samples remains challenging in untargeted lipidomic studies. In this work, we present a lipid annotation workflow based on LC-MS and MS/MS strategies, the combination of four bioinformatic tools, and a decision tree to support the accurate annotation and semi-quantification of the lipid species present in lung tissue from control mice. The proposed workflow allowed us to generate a lipid lung-based ATLAS (LiLA), which was then employed to unveil the lipidomic signatures of the Mycobacterium tuberculosis infection at two different time points for a deeper understanding of the disease progression. This workflow, combined with manual inspection strategies of MS/MS data, can enhance the annotation process for lipidomic studies and guide the generation of sample-specific lipidome maps. LiLA serves as a freely available data resource that can be employed in future studies to address lipidomic alterations in mice lung tissue.

19 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AVAna Virseda-Berdices
Ana Virseda-Berdices
RBRaquel Behar-Lagares
Raquel Behar-Lagares
JBJuan Berenguer
Juan Berenguer
JGJuan Juan González-García
Juan Juan González-García
BRBelén Fernández Requena
Belén Fernández Requena
TGthe Marathon Study Group
the Marathon Study Group
Background: Persistent liver pathology despite a sustained virologic response (SVR) to hepatitis C virus (HCV) therapy is a major clinical concern. This is particularly relevant for people with HIV (PWH) with HCV coinfection, a population prone to accelerated liver disease progression. This study aimed to characterize the plasma miRNA profile in PWH with cirrhosis one year after successful completion of HCV therapy, and to explore their relationship with metabolite alterations. Methods: This cross-sectional study enrolled 47 PWH who achieved HCV clearance with antiviral therapy. Using plasma samples collected approximately one year after completion of HCV therapy, participants were stratified into two groups based on liver stiffness measurement (LSM): compensated cirrhosis (n = 32, LSM ≥ 12.5 kPa) and non-cirrhosis (n = 15, LSM < 12.5 kPa). Plasma miRNAs and metabolites were determined using small RNA sequencing and untargeted capillary electrophoresis-mass spectrometry (CE-MS), respectively. Significantly differentially expressed (SDE) miRNAs were identified using generalized linear models (GLM) with a negative binomial distribution, and their correlation with metabolite levels was quantified using Spearman’s correlation. Results: In the cirrhosis group (n = 32), we identified a distinct signature of 15 SDE miRNAs (9 upregulated, 6 downregulated) compared to the non-cirrhotic group (n = 15), showing hsa-miR-10401-3p, hsa-miR-548ak, hsa-miR-141-3p, and hsa-miR-3940-3p the largest expression changes. miRNA-gene interaction and pathway enrichment analysis suggested that these 15 SDE miRNAs potentially regulate multiple genes involved in immune response and amino acid metabolism. In addition, correlation analyses with our metabolomic data revealed significant associations between specific SDE miRNAs and amino acids and their derivatives. Specifically, the expression of upregulated miRNAs (e.g., hsa-miR-10401-3p and hsa-miR-16-5p) was positively correlated with plasma levels of L-methionine and its derivatives, while downregulated miRNAs (e.g., hsa-miR-625-5p) were inversely correlated with L-tryptophan. Conclusions: In cirrhotic PWH with history of HCV coinfection, a distinct plasma miRNA signature linked to dysregulated amino acid metabolism is found one year after completion of HCV therapy. This underscores that the HCV cure does not equate to complete hepatic recovery, highlighting the critical need for long-term monitoring in this high-risk population.

19 August 2026 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
DGDomniki Gallou
Domniki Gallou
JMJaime Morillas-Armenta
Jaime Morillas-Armenta
MFMiguel Fernández-García
Miguel Fernández-García
BRBelén Fernández Requena
Belén Fernández Requena
SDSántiago Angulo Díaz-Parreño
Sántiago Angulo Díaz-Parreño
ALMA VILLASEÑORALMA VILLASEÑOR
ALMA VILLASEÑOR
Chronic kidney disease (CKD) has been associated with alterations in plasma-free aromatic amino acids (AAA)—tryptophan (Trp), phenylalanine (Phe), and tyrosine (Tyr)—and some downstream metabolites. However, AAA metabolism comprises a wider set of compounds, including microbiome-derived and sulfate-conjugated metabolites excreted in urine with potential biological implications. Alport syndrome (AS), a genetic condition defined by progressive renal impairment, frequently advances to CKD, suggesting that disturbances in AAA-related metabolism may also be relevant in this disorder. Nevertheless, a comprehensive quantitative method covering AAA-derived metabolites enabling an assessment of their implications in AS has not been established. Here, we introduce a novel method for the quantification of up to 43 AAA-derived metabolites in urine, including sulfated metabolites. The method is based on liquid chromatography coupled to tandem mass spectrometry and includes six deuterated internal standards to achieve reliable quantitation. A pooled healthy urine sample was characterized, and the method was validated in terms of linearity, matrix effect, accuracy, precision and sensitivity. The method was applied to urine samples from AS patients—with CKD and non-CKD—and controls. Significant alterations across groups in the concentrations of metabolites from Trp, Phe, and Tyr pathways were observed, including 4-OH-phenylacetic acid-O-sulfate. Notably, the urinary kynurenic acid (KYNA)/Trp ratio emerged as a potential indicator of renal function, showing a marked increase in AS patients with CKD, consistent with enhanced kynurenine pathway activation. Overall, this analytical platform represents a valuable tool for clinical research and for advancing the understanding of AAA-related metabolic dysregulation in renal diseases. Graphical Abstract